NCX-701. NicOx.
NicOx is developing NCX-701, a nitric oxide-releasing derivative of paracetamol (acetaminophen), for the potential treatment of inflammation and pain. The compound is currently undergoing phase III clinical trials.
Joshi
Girish P
GP
University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9068, USA. girish.joshi@utsouthwestern.edu
D000082:Acetaminophen / Q000031:analogs & derivatives / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics; D001682:Biological Availability; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004345:Drug Industry; D015507:Drugs, Investigational; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D015394:Molecular Structure; D009566:Nitrates / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology*; D010330:Patents as Topic; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D014481:United States
D000894:Anti-Inflammatory Agents, Non-Steroidal; D015507:Drugs, Investigational; D009566:Nitrates; D000082:Acetaminophen; C478738:4-(nitroxy)butanoic acid 4-acetylaminophenyl ester